Vaxxinity, Inc. (VAXX)の価格はいくらですか

Vaxxinity, Inc. (VAXX)の価格は$0.0001です

Vaxxinity, Inc. (VAXX)の時価総額は何ですか

Vaxxinity, Inc. (VAXX)の時価総額は$12.68Kです

Vaxxinity, Inc.（VAXX）配当金

Vaxxinity, Inc., a biotechnology company founded in 2014 and headquartered in Dallas, Texas, is dedicated to advancing novel therapeutic candidates for human application in the United States. Its primary areas of focus are neurological disorders and infectious diseases, particularly those caused by coronaviruses. The company's pipeline features several key programs: UB-311 is a Phase 2 clinical trial candidate targeting toxic aggregated amyloid-beta proteins in the brain, aiming to treat Alzheimer's disease. UB-312, currently in Phase 1 clinical trials, is an investigational therapy designed to address Parkinson's disease and other synucleinopathies, including Lewy body dementia and multiple system atrophy, by targeting detrimental aggregated alpha-synuclein. An anti-tau product candidate is also under development for various neurodegenerative conditions, such as Alzheimer's disease. UB-313 is being developed to alleviate migraines by modulating calcitonin gene-related peptide. An anti-PCSK9 candidate aims to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events by targeting proprotein convertase subtilisin/kexin type 9 serine protease. In the infectious disease segment, UB-612 is a Phase 3 clinical-stage candidate engineered to neutralize the SARS-CoV-2 virus.

年	配当（株式分割調整済み）	変化
提供された日付のデータは十分ではありません。

年

配当（株式分割調整済み）

変化

提供された日付のデータは十分ではありません。

年	配当	変化
提供された日付のデータは十分ではありません。

年

配当

変化

提供された日付のデータは十分ではありません。

企業	配当支払い回数	国
Vertex Pharmaceuticals Incorporated VRTX.US	0.00%	US
Argenx SE ARGX.US	0.00%	NL
Lonza Group AG LONN.SW	0.00%	CH
Samsung Biologics Co.,Ltd. 207940.KS	0.00%	KR
UCB S.A. UCB.BR	29.00%	BE

企業

配当支払い回数

国